UNSPSC 51433925: Amlodipine maleate

This classification denotes a calcium channel blocker with the molecular formula C20H25ClN2O5.C4H4O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier CQ27G2BZJM, chemically known as 3,5-pyridinedicarboxylic acid, 2-((2-aminoethoxy)methyl)-4-(2-chlorophenyl)-1,4-dihydro-6-methyl-, 3-ethyl 5-methyl ester, (+-)-, (z)-2-butenedioate (1:1) but more generally known as amlodipine maleate, which bears US NIH Compound Identifier 6435922.

UNSPSC 51433925 Amlodipine maleate (Commodity) describes a single active pharmaceutical ingredient — a calcium channel blocker commonly used in hypertension management — that state and local governments procure through medication supply contracts for emergency medical services, public health programs, and multistate cooperative purchasing vehicles. The code sees procurement activity centered on emergency responder medication supplies and broader pharmaceutical sourcing initiatives. Issuing bodies include municipal fire departments (Tampa Fire Rescue through the City of Tampa), state health and human services agencies (Texas HHS Commission), and multistate cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance, or MMCAP). These entities source amlodipine maleate and related cardiovascular medications as part of larger medication line-item contracts rather than as discrete single-drug procurements; the code typically appears bundled with other emergency pharmaceutical products or as part of statewide generic pharmaceutical master agreements serving multiple agencies and jurisdictions.

Recent activity spans Florida, Texas, and Minnesota through multistate cooperative arrangements. The City of Tampa issued IFB 26P00188 on April 24, 2026 for Advanced Life Support Medications due April 8, 2026, specifying four cardiovascular drugs (labetalol, epinephrine, adenosine, and diltiazem) with an estimated contract value of $40,000 and a Small Local Business Enterprise sheltered-market 5 percent bid discount. The Texas Health and Human Services Commission issued RFI HHS0017013 in March 2026 seeking vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program to explore direct-contracting models outside traditional pharmacy benefit managers and wholesalers, signaling state-level interest in alternative pharmaceutical sourcing channels. The Minnesota Department of Administration, through MMCAP, issued RFP S1070000015802 with a March 26, 2026 response deadline for generic multi-source pharmaceuticals and OTC products, requiring vendor pricing through three authorized wholesalers (AmerisourceBergen/Cencora, Cardinal Health, Morris & Dickson) with performance penalties of $200 to $1,500 per violation and a 3 percent administrative fee structure. Cooperative purchasing appears to drive a significant share of state and local pharmaceutical sourcing volume at this code level.